Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 1
2005 5
2006 1
2009 1
2010 2
2013 2
2014 5
2015 5
2016 2
2017 3
2018 1
2020 5
2021 9
2022 5
2023 2
2024 5
2025 12
2026 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

60 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean kensuke nakai (1 results)?
Elimusertib exhibits strong synergy with olaparib in ovarian cancer organoids through replication fork interference.
Takahashi M, Ookubo A, Yoshimura T, Toyonaga T, Saotome K, Yoshihama T, Jisaka M, Sakamaki T, Nakamura K, Sakai K, Dozen A, Oki S, Ochiai D, Sato A, Kimura Y, Itoh M, Yamagami W, Chiyoda T. Takahashi M, et al. Among authors: sakai k. Sci Rep. 2026 Jun 29. doi: 10.1038/s41598-026-59944-3. Online ahead of print. Sci Rep. 2026. PMID: 42373945 Free article.
A case of primary ovarian clear cell carcinoma with ETV6::NTRK3 fusion.
Ochiai D, Chiyoda T, Nakamura K, Takamatsu R, Jisaka M, Sakamaki T, Takahashi M, Kimura Y, Oki S, Yoshihama T, Sakai K, Nishihara H, Yamagami W. Ochiai D, et al. Among authors: sakai k. Int Cancer Conf J. 2025 Aug 20;14(4):453-457. doi: 10.1007/s13691-025-00795-6. eCollection 2025 Oct. Int Cancer Conf J. 2025. PMID: 41395567
High-Throughput Drug Screening of Clear Cell Ovarian Cancer Organoids Reveals Vulnerability to Proteasome Inhibitors and Dinaciclib and Identifies AGR2 as a Therapeutic Target.
Yoshimura T, Kamatani T, Ookubo A, Takahashi M, Itoh M, Ebisudani T, Masugi Y, Toyonaga T, Hamamoto J, Saotome K, Sakai K, Yoshihama T, Moritoki N, Shibata S, Yasuda H, Sato T, Sato TA, Aoki D, Yamagami W, Tsunoda T, Chiyoda T. Yoshimura T, et al. Among authors: sakai k. Cancer Res Commun. 2025 Jun 1;5(6):1018-1033. doi: 10.1158/2767-9764.CRC-25-0024. Cancer Res Commun. 2025. PMID: 40459063 Free PMC article.
60 results